Louis Carlton Kirby II MD
Consultant to Pharma on CNS drug and device development
Join to View Full Profile
2700 noplaceParadise Valley, AZ 85253
Dr. Kirby is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Louis Kirby is a consultant for the pharmaceutical industry specializing in developing drugs and devices for CNS indications including Alzheimer's, Parkinson's disease, migraine and ALS. Board certified in neurology and practiced for a decade before starting his clinical research company, growing it into one of the largest in the country. He has been a PI on 400 clinical trials. Served on board of directors of largest Southwest US regional chain of hospitals and served as Medical Officer to several biotech companies. Also writes novels as hobby. His first book Shadow of Eden was an Amazon bestseller.
Education & Training
University of Texas Medical Branch HospitalsResidency, Neurology, 1981 - 1985
University of Texas Medical Branch School of MedicineClass of 1981
Certifications & Licensure
AZ State Medical License 1985 - 2027
TX State Medical License 1982 - 1988
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.Stewart J Tepper, Detlef Albrecht, Jessica Ailani, Louis Kirby, Shannon Strom
CNS Drugs. 2024-12-01 - 51 citationsSingle‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moder...Carol Addy, Chris Assaid, David Hreniuk, Mark Stroh, Yang Xu
Journal of Clinical Pharmacology. 2009-07-01 - 287 citationsAβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer diseaseEliezer Masliah, Lawrence A. Hansen, Anthony Adame, Leslie Crews, Frederique Bard
Neurology. 2005-01-11
Press Mentions
Cortexyme Assembles World Class Clinical Advisory Board to Support Its Alzheimer’s Disease Clinical Development ProgramSeptember 27th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
